EL PASO, Texas--(BUSINESS WIRE)--Premier Biomedical, Inc. (OTCBB:BIEI) a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer’s disease, multiple sclerosis (MS), and traumatic brain injury, announced today that their exclusive worldwide licensor, Marv Enterprises, LLC has received a Notice of Allowance from the U.S. Patent and Trademark Office for 20 claims in their broad base patent application, "Utilization of Stents for the Treatment of Blood-Bourne Carcinomas," covering the basic technology underpinning Premier’s on-going research into new treatments for many of today’s most debilitating diseases.
William Hartman, President and CEO of Premier Biomedical, said, “This is great, but not unexpected, news for us, and affirms the novelty of our approach for developing effective treatments. We are very confident that our technology is sound and very effective in fighting many diseases that have heretofore been incurable or at least very difficult to cure. Our early lab tests bear out our assessment of the effectiveness of this technology.” Mr. Hartman went on to say, “Now, we know that our treatments are also revolutionary. Even with this good patent news, covering much of our work to date, we will continue to issue patent applications on subsequent experimental treatments to ensure proprietary content for Premier Biomedical, Inc. and our stockholders."
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, in collaboration with the University of Texas at El Paso and US Department of Defense, specifically targeting the treatment of Alzheimer's disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.